Product Name :
Radezolid
Description:
Radezolid, also known as RX-1741, is a novel oxazolidinone antibiotic being developed by Rib-X Pharmaceuticals, Inc. for the treatment of serious multi-drug–resistant infections. Radezolid has completed two phase-II clinical trials. One of these clinical trials was for uncomplicated skin and skin-structure infections (uSSSI) and the other clinical trial was for community acquired pneumonia (CAP).
CAS:
869884-78-6
Molecular Weight:
438.45
Formula:
C22H23FN6O3
Chemical Name:
N-{[(5S)-3-[2-fluoro-4′-({[(2H-1,2,3-triazol-4-yl)methyl]amino}methyl)-[1,1′-biphenyl]-4-yl]-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide
Smiles :
CC(=O)NC[C@H]1CN(C2=CC(F)=C(C=C2)C2=CC=C(CNCC3C=NNN=3)C=C2)C(=O)O1
InChiKey:
BTTNOGHPGJANSW-IBGZPJMESA-N
InChi :
InChI=1S/C22H23FN6O3/c1-14(30)25-12-19-13-29(22(31)32-19)18-6-7-20(21(23)8-18)16-4-2-15(3-5-16)9-24-10-17-11-26-28-27-17/h2-8,11,19,24H,9-10,12-13H2,1H3,(H,25,30)(H,26,27,28)/t19-/m0/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥360 days if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Radezolid, also known as RX-1741, is a novel oxazolidinone antibiotic being developed by Rib-X Pharmaceuticals, Inc. for the treatment of serious multi-drug–resistant infections. Radezolid has completed two phase-II clinical trials. One of these clinical trials was for uncomplicated skin and skin-structure infections (uSSSI) and the other clinical trial was for community acquired pneumonia (CAP).|Product information|CAS Number: 869884-78-6|Molecular Weight: 438.45|Formula: C22H23FN6O3|Chemical Name: N-{[(5S)-3-[2-fluoro-4′-({[(2H-1,2,3-triazol-4-yl)methyl]amino}methyl)-[1,1′-biphenyl]-4-yl]-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide|Smiles: CC(=O)NC[C@H]1CN(C2=CC(F)=C(C=C2)C2=CC=C(CNCC3C=NNN=3)C=C2)C(=O)O1|InChiKey: BTTNOGHPGJANSW-IBGZPJMESA-N|InChi: InChI=1S/C22H23FN6O3/c1-14(30)25-12-19-13-29(22(31)32-19)18-6-7-20(21(23)8-18)16-4-2-15(3-5-16)9-24-10-17-11-26-28-27-17/h2-8,11,19,24H,9-10,12-13H2,1H3,(H,25,30)(H,26,27,28)/t19-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Belvarafenib} web|{Belvarafenib} MAPK/ERK Pathway|{Belvarafenib} Protocol|{Belvarafenib} Formula|{Belvarafenib} custom synthesis|{Belvarafenib} Epigenetic Reader Domain} |Shelf Life: ≥360 days if stored properly.{{Betamethasone} web|{Betamethasone} Vitamin D Related/Nuclear Receptor|{Betamethasone} Protocol|{Betamethasone} Description|{Betamethasone} custom synthesis|{Betamethasone} Epigenetic Reader Domain} |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:24633055 |Drug Formulation: To be determined|HS Tariff Code: 382200|Products are for research use only. Not for human use.|